Victory Capital Management Inc Codiak Bio Sciences, Inc. Transaction History

Victory Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.32 - $0.9 $1,707 - $4,802	-5,336 Reduced 7.17%	69,102 $27,000
Q3 2022 Nov 02, 2022	SELL	$0.82 - $3.19 $19 - $76	-24 Reduced 0.03%	74,438 $58,000
Q2 2022 Aug 01, 2022	SELL	$2.24 - $6.96 $273,217 - $848,925	-121,972 Reduced 62.09%	74,462 $214,000
Q1 2022 May 04, 2022	SELL	$4.3 - $12.95 $61,171 - $184,226	-14,226 Reduced 6.75%	196,434 $985,000
Q4 2021 Feb 07, 2022	SELL	$10.0 - $16.78 $180,910 - $303,566	-18,091 Reduced 7.91%	210,660 $2.35 Million
Q3 2021 Nov 02, 2021	SELL	$15.58 - $22.88 $22,263 - $32,695	-1,429 Reduced 0.62%	228,751 $3.74 Million
Q2 2021 Aug 03, 2021	SELL	$11.72 - $26.81 $518,961 - $1.19 Million	-44,280 Reduced 16.13%	230,180 $4.27 Million
Q1 2021 May 04, 2021	BUY	$13.49 - $31.53 $2.43 Million - $5.68 Million	180,157 Added 191.04%	274,460 $4.14 Million
Q4 2020 Feb 01, 2021	BUY	$7.9 - $32.3 $744,993 - $3.05 Million	94,303 New	94,303 $3.05 Million

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.